Cargando…

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

Biopharmaceuticals are drugs which are based on naturally occurring proteins (antibodies, receptors, cytokines, enzymes, toxins), nucleic acids (DNA, RNA) or attenuated microorganisms. Immunogenicity of these agents has been commonly described and refers to a specific antidrug antibody response. Suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creeke, Paul I., Farrell, Rachel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526949/ https://www.ncbi.nlm.nih.gov/pubmed/23277789 http://dx.doi.org/10.1177/1756285612469264

Ejemplares similares

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
por: Manceau, Philippe, et al.
Publicado: (2014)

Early stage and long term treatment of multiple sclerosis with interferon-β
por: Applebee, Angela, et al.
Publicado: (2009)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis
por: Fox, Edward, et al.
Publicado: (2014)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2014)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis
por: Lau, Alexander Y, et al.
Publicado: (2017)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis
por: Gandhi, Kaushal S., et al.
Publicado: (2010)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Multiple Sclerosis
por: Ramagopalan, Sreeram, et al.
Publicado: (2011)

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
por: Zhornitsky, Simon, et al.
Publicado: (2015)

Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
por: Link, Jenny, et al.
Publicado: (2017)

Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ
por: Waddington, Kirsty E., et al.
Publicado: (2020)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016)

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
por: Järvinen, Elina, et al.
Publicado: (2019)

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ofpk81eq2hclm952rlut9ne1ci